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Abstract (249 words) 
 
Background Beta-blockers are recommended in stable coronary artery disease (CAD) 
to improve symptoms and survival, and reduce heart rate (HR), but their 
administration is limited due to contraindications or intolerability.  
Objective To use CLARIFY, a prospective registry of patients with stable CAD (45 
countries), to explore HR control and beta-blocker use.  
Methods We analyzed the CLARIFY population according to beta-blocker use. 
Results Data on beta-blocker use was available for 33 243 patients, in whom HR was 
68±11 bpm; patients with angina, previous myocardial infarction, and heart failure 
had HRs of 69±12, 68±11, and 70±12 bpm, respectively. 75% of these patients were 
receiving beta-blockers. Bisoprolol (34%), metoprolol tartrate (15%) or succinate 
(13%), atenolol (15%), and carvedilol (12%) were mostly used; mean dosages were 
49%, 76%, 35%, 53%, and 45% of maximum recommended doses, respectively. 
Patients aged <65 years were more likely to receive beta-blockers than patients ≥75 
years (P<0.0001). Gender had no effect. Subjects with HR≤60 bpm were more likely 
to use beta-blockers than patients with HR≥70 bpm (P<0.0001). Patients with angina, 
previous myocardial infarction, heart failure, and hypertension were more 
frequently receiving beta-blockers (all P<0.0001), and those with PAD and 
asthma/COPD less frequently (both P<0.0001). Beta-blocker use varied according to 
geographical region (from 87% to 67%). 
Conclusion Three-quarters of patients with stable CAD receive beta-blockers. Even 
so, HR is insufficiently controlled in many patients, despite recent ACCF/AHA 
guidelines for the management of CAD. There is still much room for improvement in 
HR control in the management of stable CAD. 
 
Keywords: CLARIFY; stable CAD; beta-blocker; heart rate 
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Introduction 
 
Elevated heart rate is known to have a detrimental effect on the occurrence of 
myocardial ischemia and is a well-established risk factor in patients with coronary 
artery disease (CAD) (1-5). This is recognized in the recent American College of 
Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines for the 
management of stable CAD, which stress the prognostic importance of elevated 
heart rate and recommend that beta-blocker dose be adjusted to limit resting heart 
rate to 55–60 beats per minute (bpm) (6). Despite the weight of evidence, several 
observational studies suggest that this target is not systematically achieved in clinical 
practice. Moreover, it appears that this may be traced to suboptimal prescription of 
beta-blockers. Indeed, data from the Euro Heart Survey show that only two-thirds of 
patients with stable angina are prescribed a beta-blocker (7). The actual rate of 
administration  may even be lower, since a recent study based on the UK General 
Practice Research Database found that a quarter of patients taking a beta-blocker in 
primary care appear to discontinue it within one year, rising to half of patients by 3 
years (8). The reasons for this failure to align with international guidelines include 
contraindications or tolerability issues, which may limit beta-blocker use and up-
titration in clinical practice.  
 
Beta-blockers act by competitive inhibition of the effects of circulating 
catecholamines on the beta-adrenergic receptors, and are associated with a variety 
of physiological actions, including reduction in blood pressure and myocardial 
contractility, as well as heart rate. Current international guidelines recommend beta-
blockers as the initial treatment for angina in patients with stable CAD (6,9). Beta-
blockers are also widely used in asymptomatic patients with CAD, particularly in 
those who have suffered a myocardial infarction (MI) or have left ventricular systolic 
dysfunction or heart failure; in both groups, a reduction in mortality has been 
documented (10-12). At least part of the beneficial action of beta-blockers is 
believed to be related to the lowering of elevated heart rate.  
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With these issues in mind, we set out to perform an analysis of the use of beta-
blockers in the CLARIFY (ProspeCtive observational LongitudinAl RegIstry oF patients 
with stable coronary arterY disease) registry. CLARIFY is an ongoing international 
prospective observational longitudinal registry that included a broad population of 
over 33 000 patients living in 45 countries, receiving standard management for 
stable CAD (13,14). It has already been reported that 75% of CLARIFY patients were 
receiving a beta-blocker (13). In the analysis described herein, we used the CLARIFY 
database to explore the use of individual beta-blockers and their dosages in patients 
with stable CAD, as well as the distribution of beta-blocker use according to patient 
profile (e.g., age, sex, and concomitant diseases) and geographical location to 
determine how current practice reflects the recent guideline recommendations in 
terms of heart rate control in CAD (6). 
 
Methods 
 
Study design and patients 
The 2898 CLARIFY physicians each recruited between 10 and 15 consecutive patients 
with stable CAD (i.e. documented MI, coronary artery bypass grafting [CABG], or 
percutaneous coronary intervention [PCI] >3 months previously, or angiographic 
demonstration of >50% coronary stenosis, or chest pain with evidence of myocardial 
ischaemia [stress electrocardiogram]). Patients with recent (<3 months) 
hospitalization for cardiovascular reasons (including revascularization), planned 
revascularization, or any serious condition expected to affect follow-up were 
excluded. Further details of the inclusion and exclusion criteria, as well as the study 
design, have been published elsewhere (13,14).  
 
CLARIFY is ongoing in 45 countries in Europe, the Americas, Africa, Middle East, and 
Asia/Pacific (13). One target was to cover an epidemiologically representative 
population in each of the countries (i.e. 25 patients per million inhabitants [range 
12.5 to 50]). Participating physicians were selected on the basis of geographic 
distribution. CLARIFY is carried out in accordance with the principles laid out in the 
Declaration of Helsinki and its revisions. Local ethical approval was obtained in all 
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countries prior to recruitment. All patients gave written informed consent. The study 
is registered (ISRCTN43070564). The first patient was included on November 26, 
2009 and recruitment was completed on June 30, 2010 (13). 
 
Data were collected at baseline on demographics, risk factors and lifestyle, medical 
history, physical condition and vital signs, current symptoms, and current treatments 
using standardized electronic case report forms. Heart rate was measured by 
electrocardiography, or by palpation when electrocardiographic data was not 
available. We analyzed the CLARIFY population according to the use of different 
beta-blockers. We also analyzed beta-blocker use according to patient profile, 
including: age (<65 years, 65-74 years, or ≥75 years); gender; heart rate (≤60 bpm, 
61-69 bpm, or ≥70 bpm); presence of angina; Canadian Cardiovascular Society (CCS) 
class of angina; presence of heart failure defined according to the New York Heart 
Association (NYHA) classification; diabetes; asthma/chronic obstructive pulmonary 
disease (COPD); hypertension; peripheral artery disease; and a history of previous 
MI. We also explored the use of different beta-blockers according to geographic 
region.  
 
Data collection and statistical methods 
Data are presented using descriptive statistics with numbers (%) of patients for 
categorical variables, and mean and standard deviation for continuous variables. 
Comparisons between the groups were made using Pearson’s χ2 test for categorical 
variables. All data were collected and analyzed by the independent academic 
Robertson Centre for Biostatistics at the University of Glasgow, UK. The SAS (version 
9.2) statistical program was used and all tests were two-sided with a significance 
level of 5%.  
 
Role of funding source 
The study was designed and conducted by the investigators, supported by research 
grants from Servier, France. The sponsor had no role in study design, data collection 
and analysis, decision to publish, or writing of the manuscript, but did assist with the 
set up and management of the study in each country. 
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Results 
 
Information on beta-blocker use was available for 33 243 (99.9%) patients. Of these, 
24 984 (75%) were receiving a beta-blocker. Patients receiving a beta-blocker had a 
mean heart rate of 68±11 bpm. There were 7315 patients with angina at baseline, 
with a mean heart rate of 69±12 bpm. Of these, 1820 (25%) had heart rate ≤60 bpm. 
Heart rate was 68±11 bpm in 19 844 patients with previous MI and 70±12 bpm in 
4943 patients with NYHA class II/III heart failure at baseline.  
 
As regards the individual beta-blockers, most patients were receiving bisoprolol 
(34%), metoprolol tartrate (15%) or succinate (13%), atenolol (15%), carvedilol 
(12%), or nebivolol (6%) (Table 1). On the whole, mean beta-blocker dosages were 
within the therapeutic dosage range for angina or chronic heart failure (15-17). 
Mean dosages of bisoprolol, metoprolol tartrate, metoprolol succinate, atenolol and 
carvedilol were 49%, 76%, 35%, 53%, and 45% of the maximum recommended dose. 
Among patients treated with beta-blockers, 2047 (8%) had intolerance or 
contraindications to these agents, mainly fatigue (716 patients, 2.9% of total [or 35% 
of the patients with intolerance or contraindications]), bradycardia (590 patients, 
2.4% [or 29%]), erectile dysfunction (398 patients, 1.6% [or 19%]), hypotension (369 
patients, 1.5% [or 18%]), dizziness (255 patients, 1.0% [or 12%]), or exacerbation of 
asthma or COPD (199 patients, 0.8% [or 10%]). 
 
The rates of beta-blocker use according to age, gender, and heart rate are presented 
in Table 2. Younger patients (<65 years) were significantly more likely to receive a 
beta-blocker than older patients (≥75 years) (78% versus 69%, P<0.0001). There was 
no difference in beta-blocker use according to gender. Subjects with low heart rate 
(≤60 bpm) were more likely to be on a beta-blocker than patients with elevated 
heart rate (≥70 bpm) (80% versus 70%, P<0.0001). As regards beta-blocker dosages 
in patients with differing levels of heart rate, the mean dosage of atenolol was 
52.8±27.8 mg/day in patients with heart rate between 61 and 69 bpm, and 
54.3±27.3 mg/day in those with heart rate ≥70 bpm. The corresponding dosages for 
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other beta-blockers were: bisoprolol 5.0±3.0 and 5.1±3.0 mg/day, metoprolol 
tartrate 74.0±49.8 and 74.0±51.7 mg/day, and carvedilol 22.7±15.9 and 22.8±16.4 
mg/day.  
 
The rate of beta-blocker use according to medical history is presented in Table 3. 
There were significantly higher rates of beta-blocker use in patients with angina 
(79% versus 74% with no angina), and greater levels in patients with higher CCS class 
(75% in CCS class I, 80% in class II, and 81% in class III/IV). Of the angina patients with 
heart rate ≤60 bpm, 1507 (83%) were taking a beta-blocker. Patients with previous 
MI were more likely to receive beta-blocker (79% versus 70% in those without 
history of MI). In patients with MI in the same calendar year or the calendar year 
preceding recruitment (n=4844), the rate of BB use was 82%. Higher rates were also 
found in patients with heart failure (74% with no heart failure versus 83% in NYHA 
class II/III), diabetes (77% versus 74% with no diabetes), and hypertension (77% 
versus 70% with no hypertension) (all P<0.0001). Lower rates of beta-blocker use 
were observed in patients with PAD (71% versus 76% without PAD) (P<0.0001). 
Patients with asthma/COPD were considerably less likely to be receiving a beta-
blocker (51% versus 77% without asthma/COPD) (P<0.0001).  
 
As regards comorbidities, 43% of patients with NYHA class II/III heart failure were 
taking bisoprolol, 14% carvedilol, 12% metoprolol tartrate, 14% metoprolol 
succinate, 8% nebivolol, and 5% atenolol. The mean dosages of beta-blocker in the 
patients with NYHA class II/III heart failure were: bisoprolol 5.5±3.1 mg/day, 
carvedilol 23.5±15.7 mg/day, metoprolol tartrate 72.8±51.1 mg/day, metoprolol 
succinate 69.8±42.6 mg/kg, nebivolol 4.7±1.7 mg/day, and atenolol 54.7±28.3 
mg/day. Similar distribution was observed for the individual beta-blockers in patients 
with diabetes (bisoprolol, 31%; metoprolol tartrate 16% and succinate 11%; atenolol, 
16%; carvedilol, 15%; nebivolol, 5%) and PAD (bisoprolol, 36%; metoprolol tartrate 
11% and succinate 11%; atenolol, 12%; carvedilol, 15%; nebivolol, 8%). There was no 
clear pattern in the distribution of the use of individual beta-blockers in other 
patient profiles (data not shown).  
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There was a substantial variation in beta-blocker use according to geographical 
region. Rates of beta-blocker use were highest in Russia and the Ukraine (87%), the 
Middle East (87%), and Europe (excluding UK) (77%), and lowest in Canada, South 
Africa, Australia, and UK (67%). The other regions had rates around 70% (Asia, 71%; 
India, 70%; and Central/South America, 70%). There were considerable differences in 
the use of various agents between the regions, with bisoprolol dominating in Europe, 
Russia, Ukraine, and the Middle East, and metoprolol dominating in India, and 
Central and South America (Figure 1).  
 
Discussion 
 
The mean heart rate in the CLARIFY population was 68±11 bpm. Within this 
population, mean heart rates in patients with angina, previous MI, and heart failure 
were 69±12, 68±11, and 70±12 bpm, respectively. Three-quarters (75%) of patients 
with stable CAD in the CLARIFY registry were receiving treatment with a beta-
blocker. Patients with angina, heart failure and recent MI were more likely to be 
receiving beta-blocker: 79% of angina patients, 83% of heart failure patients, and 
82% of patients with recent MI. The most commonly used beta-blockers were 
bisoprolol (34%) and metoprolol tartrate (15%) or succinate (13%). The Euro Heart 
Survey, which collected data in 2002 (18), reported that about two thirds (67%) of 
patients with stable angina in Europe were on a beta-blocker (19). Higher rates of 
beta-blocker use in CLARIFY, which collected data in 2009 to 2010, imply that there 
has been some improvement in the management of these patients in recent years.  
 
The use of beta-blockers has also been explored in the REACH (Reduction of 
Atherothrombosis for Continued Health) registry, which included nearly 45 000 
stable outpatients with and without CAD in 2004 (20). Two thirds (67%) of REACH 
patients with prior MI were receiving a beta-blocker at baseline, versus 57% of 
patients with CAD but no prior MI (20). Like the CLARIFY patients, the REACH beta-
blocker patients were significantly younger and more likely to have hypertension or 
heart failure (all P<0.001); also like CLARIFY, there was no significant difference in 
beta-blocker use according to gender. REACH also assessed cardioprotective benefits 
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of beta-blockers in stable CAD. Since the time of the landmark beta-blocker trials in 
heart failure and post-MI (10-12,21), these agents have been used to prevent MI or 
death, and their cardioprotective effects have been broadly extrapolated to all 
patients with stable CAD, including those without MI. It is not known, however, if 
these extrapolations are justified. Moreover, the long-term efficacy of beta-blockers 
in patients treated with contemporary medical therapies is unclear, even in patients 
with prior MI. The REACH investigators demonstrated that, in a contemporary stable 
CAD population, beta-blocker use is not associated with a lower event rate of 
cardiovascular events at 44-month follow-up, even among patients with a history of 
MI (20). 
 
Our results regarding the use of individual agents confirm that majority of physicians 
are following evidence-based guidelines on the management of heart failure (17), 
since 83% of patients with NYHA class II/III heart failure are prescribed beta-blockers 
known to be effective in heart failure, such as bisoprolol (43%), carvedilol (14%) or 
metoprolol (14% succinate and 12% tartrate). As regards other comorbidities, we 
also observed that patients with comorbid PAD and diabetes are well treated. This is 
an important point since beta-blockers are not contraindicated in PAD and diabetes.  
 
While beta-blockers are clearly not being withheld in patients who require them, 
there is an indication that physicians tend to prescribe considerably lower doses 
than those recommended (15-17). This finding is in line with the reports from several 
observational studies (7,8,22). For example, mean beta-blocker dosages in CLARIFY 
are similar to those reported from the Euro Heart Survey (7). Generally, while beta-
blockers are the most frequent drug class prescribed to patients with stable CAD, 
they are used at low doses (7). In the Euro Heart Survey, this was linked to a concern 
over the risk for adverse effects or caution related to comorbidities such as 
respiratory diseases (23). The same may be true in CLARIFY, insofar as 19% of the 
patients on beta-blockers have symptoms indicative of intolerance or 
contraindications to the treatment. The submaximal dosing may be partly due to the 
absence of recommended dosages in patients with stable CAD without heart failure. 
In patients with heart failure, the dosages of beta-blockers were also lower than 
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recommended dosages for their condition, generally at 50% of target dosages, for 
bisoprolol (6 mg/day instead of the target of 10 mg/day), metoprolol (73 mg/day for 
tartrate and 70 mg/day for succinate, versus target dose of 200 mg/day), and 
carvedilol (24 mg/day versus target dose of 50 mg/day).  
 
Patients with low heart rate were significantly more likely to receive a beta-blocker. 
However, 70% of patients with heart rate ≥70 bpm were on a beta-blocker. While 
this suggests that beta-blockers were prescribed to the majority of patients with 
elevated heart rate, it may also indicate that the heart rate–lowering effects of beta-
blockers are not always sufficient to reduce heart rate below 70 bpm. The CLARIFY 
data indicate that global control of heart rate is poor in daily clinical practice (13). 
Among 7315 patients with angina symptoms, only 1820 (25%) had heart rate ≤60 
bpm. This may reflect the lack of knowledge of the optimal resting heart rate among 
physicians. Guidelines in stable CAD and acute MI recommend heart rates of 55–60 
bpm for prevention of myocardial ischemia and prognostic benefits (6). Indeed, it is 
now well established that patients with heart rate ≥70 bpm have a higher risk of MI 
and other major outcomes compared with patients with heart rate <70 bpm 
(2,24,25). Moreover, there is evidence that clinical benefits are tightly associated 
with magnitude of heart rate reduction (26-28). In this context, the use of more than 
one heart rate–reducing agent to achieve lower heart rate may be beneficial in 
patients with stable CAD and elevated heart rate (13). 
 
Geographical differences in beta-blocker use are consistent with other reports in 
angina and in heart failure (19,29,30). The Euro Heart Survey reported substantial 
geographical differences within Europe, with 52% of angina patients in Western 
Europe receiving beta-blocker versus 77% patients in Central Europe (19). Some of 
the variations in the use of different beta-blockers may be due to cultural habits or 
availability of certain agents, rather than a clinical decision per se.  
 
The limitations associated with investigations within the CLARIFY registry have been 
extensively detailed elsewhere (13). Most importantly, the CLARIFY population was 
not randomly selected and not consecutive, but within each center the data were 
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collected consecutively. The centers were not selected randomly, but their choice 
was based on the ability to enroll patients into the registry.  
 
Conclusions 
 
Patients with stable CAD are likely to receive a beta-blocker (75% of patients), 
particularly when they have angina, heart failure or recent MI), with the most 
common agents being bisoprolol and metoprolol. Despite this, heart rate is 
insufficiently controlled in a high proportion of patients, which may have a negative 
effect on their health status. Recent ACCF/AHA guidelines suggest that the heart 
rate, rather than the beta-blocker dose, should guide the use of heart rate–reducing 
agents in clinical practice (6). Clearly, there is still much room for improvement in 
heart rate control in patients with stable CAD. 
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Table 1. Use of beta-blockers in the CLARIFY population (33 243 patients). 
aPercentages of patients receiving any beta-blocker (patients could be taking more than one beta-
blocker at the baseline visit). According to recommendations in stable anginab (15,16) and/or chronic 
heart failurec (17)..d75% of the total CLARIFY populations.  
 
 Patients, n (%)a Dosage (mg/day), 
mean±SD 
Recommended 
rangeb (mg/day) 
Any beta-blocker 24 984d   
Atenolol 3775 (15%) 52.59±27.01 25–100b 
Bisoprolol 8506 (34%) 4.92±2.95 2.5–10b/10c 
Carvedilol 2905 (12%) 22.68±15.9 50c 
Metoprolol tartrate 3862 (15%) 75.65±51.96 50–100b 
Metoprolol succinate 3127 (13%) 70.86±44.55 200c 
Nebivolol 1408 (6%) 4.68±1.83 2.5–5b/10C 
At least one other beta-
blocker 
1390 (6%)   
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Table 2. Beta-blocker use in patients according to age, gender, and heart rate. 
*P value for between-group difference. 
 
 Patients with 
data available  
Any beta-
blocker 
Age   
• Age <65 years 17 214 13 473 (78%) 
• Age 65-74 years 10 812 7937 (73%) 
• Age ≥75 years 5197 3563 (69%) 
P-value*  P<0.0001 
Gender   
• Males 25 751 19 366 (75%) 
• Females 7481 5610 (75%) 
P-value*  P=0.71 
Heart rate   
• ≤60 bpm 9828 7854 (80%) 
• 61-69 bpm 9616 7489 (78%) 
• ≥70 bpm 13 795 9637 (70%) 
P-value*  P<0.0001 
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Table 3. Beta-blocker use in patients according to medical history. 
*P value for between-group difference. CCS=Canadian Cardiovascular Society. NYHA=New York Heart 
Association. COPD=chronic obstructive pulmonary disease. MI=myocardial infarction. PAD=peripheral 
arterial disease. 
 
 Patients with 
data available  
Any beta-
blocker 
Angina   
• Angina 7315 5748 (79%) 
• No angina 25 922 19 230 (74%) 
P-value*  P<0.0001 
Angina CCS class   
• Class I 2091 1572 (75%) 
• Class II 3888 3097 (80%) 
• Class III/IV 1332 1075 (81%) 
P-value*  P<0.0001 
Heart failure   
• No heart failure 28 289 20 863 (74%) 
• NYHA  class II 4135 3446 (83%) 
• NYHA class III 808 665 (82%) 
P-value**  P<0.0001 
Diabetes   
• Diabetes 9691 7487 (77%) 
• No diabetes 23 545 17 491 (74%) 
P-value*  P<0.0001 
Asthma/COPD   
• Asthma/COPD 2452 1252 (51%) 
• No asthma/COPD 30 785 23 730 (77%) 
P-value*  P<0.0001 
Myocardial infarction   
• Previous MI 19 844 15 645 (79%) 
• No previous MI 13 393 9335 (70%) 
P-value*  P<0.0001 
MI in the last two calendar years 
• Previous MI 4844 3965 (82%) 
• No previous MI 28399 21 019 (74%) 
P-value*  P<0.0001 
Hypertension   
• Hypertension 23 583 18 260 (77%) 
• No Hypertension 9653 6718 (70%) 
P-value*  P<0.0001 
PAD   
• PAD 3253 2322 (71%) 
• No PAD 29 982 22 655 (76%) 
P-value*  P<0.0001 
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Figure 1. Distribution of beta-blocker use by geographical region. 
SA=South Africa. 
 
 
